8-K
filed December 2, 2025, 6:59 PM ET
ticker CERO
CIK 0001870404
other material
confidence high
sentiment neutral
materiality 0.70
CERO Therapeutics enters new equity line for up to $14.6M from Keystone Capital
CERO THERAPEUTICS HOLDINGS, INC.
- Company entered a new Common Stock Purchase Agreement with Keystone Capital for up to $14,591,939 of common stock.
- Prior agreements (Feb 2024, Nov 2024, July 2025) raised ~$10.4M total: ~$4.4M (Feb), ~$3.1M (Nov), ~$2.9M (July).
- Minimum stock price for purchases set at $0.02; single fixed purchase limited to 10,000 shares or $100,000.
- Investor's beneficial ownership capped at 4.99% of outstanding shares; registration rights granted.
- Agreement is a continuation of the existing equity line program; no additional commitment shares required.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CERO THERAPEUTICS HOLDINGS, INC. entered into Registration Rights Agreement with an institutional investor (the "Investor") (effective 2025-11-26).
- Action
- entry
- Counterparty
- an institutional investor (the "Investor")
- Effective
- 2025-11-26
Exact text from the filing
Concurrent with the execution of the Purchase Agreement, the Company entered into a registration rights agreement with the Investor (the “Registration Rights Agreement”), pursuant to which the Company agreed to provide the Investor with customary registration rights related to the shares issued under the Registration Rights Agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CERO THERAPEUTICS HOLDINGS, INC. entered into Purchase Agreement with an institutional investor (the "Investor") valued at up to $14,591,939 (effective 2025-11-26).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an institutional investor (the "Investor")
- Value
- up to $14,591,939
- Effective
- 2025-11-26
Exact text from the filing
On November 26, 2025, the Company entered into a purchase agreement (the “Purchase Agreement”) with the Investor, pursuant to which the Company may issue and sell to the Investor, from time to time as provided in the Purchase Agreement, and the Investor shall purchase from the Company up to $14,591,939 of the Company’s outstanding shares of Common Stock, subject to the satisfaction of the conditions in the Purchase Agreement.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.